DigiPath to Integrate Pathology Scanners in Kanteron's Launch of First Translational Medical Imaging System

Share Article

DigiPath, Inc. (OTCBB: DIGP) will integrate pathology scanners in Kanteron Systems' launch of the world's first Translational Medical Imaging System (“TMIS”) at the Radiology Society of North America (“RSNA”) annual meeting in Chicago, December 1-5, 2013. TMIS will be a fully integrated hardware and software solution for radiology, genetic and pathology workflow.

DigiPath, Inc. (OTCBB: DIGP) will integrate pathology scanners in Kanteron Systems' launch of the world's first Translational Medical Imaging System (“TMIS”) at the Radiology Society of North America (“RSNA”) annual meeting in Chicago, December 1-5, 2013. TMIS will be a fully integrated hardware and software solution for radiology, genetic and pathology workflow.

Translational research is an emerging field that aims to provide a better understanding of the molecular basis of disease, which in turn will inform clinical practice and ultimately improve human health.

Kanteron Systems' cutting-edge medical imaging and hospital information solution TIMS unifies for the first time molecular imaging (genomes, proteins and metabolic), functional imaging (physiology), and anatomical imaging (anatomy), graphs, and workflows along with their increasingly voluminous amounts of metadata, to produce the most complete and unified visualization, enabling researchers and clinicians to reach precise diagnostics with unparalleled ease and speed.

TMIS is fully interoperable with PACS-Vendor Neutral Archive, EHR, RIS, and LIS via standards-compliant protocols and formats (like DICOM and HL7). TMIS also includes a zero-footprint remote single interface for access to PACS, VNA, RIS, WorkList Server, radiology, genetics and Digital Pathology image viewer that includes zoom, pan, measure, annotate, and report tools functions.

DigiPath’s PathScope™ provides the hardware functions to affordably digitize pathology slides. PathScope reduces the adoption cost of digital pathology by over 50%, with the ability to hold between 1 to 200 slides, up to 5 objectives, in both scanning and live video modes.

“Kanteron’s clients have demanded the ability to integrate radiology, pathology and genetics data into a single platform, including an affordable digital pathology scanner,” stated Jorge Cortell, Chief Executive Officer of Kanteron Systems. “With PathScope™, we will be able to offer our clients the most cost effective solution available on the market today.”

“TMIS takes the first step towards managing big data generated by our research clients,” said Eric Stoppenhagen, President of DigiPath, Inc. “By combining TMIS with PathScope, our clients will be able to mine the big data for future research gains in cost effective manner.“

Stop by RSNA 2013 Booth # B7510 to see the benefits of TMIS and PathScope.

Visit http://www.kanteron.com and http://www.digipath.biz for futher information.

About Kanteron Systems
Kanteron Systems is a leading open-source software company founded in 2005, specializing in medical imaging. Our award-winning Translational PACS enables full-resolution real-time telepathology in standard DICOM image format (an industry first), as well as genetic and radiology information and imaging storage and workflow management, and healthcare data integration. With offices in New York (USA), Lima (Peru), and Valencia (Spain), Kanteron Systems provides advanced medical imaging software solutions to some of the largest healthcare networks in the world (like the NHS in the UK, ISSSTE in Mexico, and EsSalud in Peru). For more information please visit: http://www.kanteron.com or send an email to info(at)kanteron(dot)com.

About DigiPath, Inc.
DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPath’s advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 750 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide. Please visit http://www.digipath.biz for more information.

SAFE HARBOR STATEMENT
This Press Release may contain certain forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. DigiPath has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect DigiPath's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause DigiPath's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. DigiPath undertakes no obligation to update or provide advice in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

DigiPath Media Relations
Visit website